Results 1 to 10 of about 12,211 (152)
Extended interval dosing of natalizumab: a two-center, 7-year experience
Therapeutic Advances in Neurological Disorders, 2014 Background: The enthusiasm for natalizumab, a highly efficacious agent in the treatment of multiple sclerosis (MS), has been tempered by the risks of progressive multifocal leukoencephalopathy associated with its use, and strategies to minimize those ...
Roberto Bomprezzi, Siddharama Pawate
exaly +2 more sources
Real-World Effectiveness of Natalizumab in Korean Patients With Multiple Sclerosis
Frontiers in Neurology, 2021 Background and Purpose: Natalizumab is a highly efficacious disease-modifying therapy for relapsing-remitting multiple sclerosis (MS). Data on the efficacy and safety profile of natalizumab in Asian patients with MS are limited.
Ki Hoon Kim +4 more
doaj +1 more source
Arquivos de Neuro-Psiquiatria, 2021 Background: The real-world effectiveness of natalizumab in people with relapsing multiple sclerosis (PwRMS) in Argentina and Chile has not been reported.
Maria Celica Ysrraelit +7 more
doaj +1 more source
Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis. [PDF]
PLoS ONE, 2012 Natalizumab is an effective monoclonal antibody therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS) and interferes with immune cell migration into the central nervous system by blocking the α(4) subunit of very-late activation ...
Andrea Harrer +11 more
doaj +1 more source
Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses
Frontiers in Neurology, 2021 Background: Plasma concentration of natalizumab falls above the therapeutic threshold in many patients who, therefore, receive more natalizumab than necessary and have higher risk of progressive multifocal leukoencephalopathy.Objective: To assess in a ...
Jose M. Serra López-Matencio +10 more
doaj +1 more source
Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020 Objective To determine multiple sclerosis patient characteristics that predict a shorter duration of natalizumab treatment. Methods The Tysabri Outreach: Unified Commitment to Health database was reviewed to identify patients treated with natalizumab at ...
Devon S Conway +3 more
doaj +1 more source
Effects of natalizumab treatment on Foxp3+ T regulatory cells.
PLoS ONE, 2008 BackgroundNatalizumab, a monoclonal humanized antibody targeting the alpha-4 chain of very late activation antigen 4 (VLA-4) exerts impressive therapeutic effects in patients with relapsing-remitting multiple sclerosis. Our objective was to study impacts
Max-Philipp Stenner +6 more
doaj +1 more source
Influence of natalizumab on resting-state connectivity in patients with multiple sclerosis
Journal of Central Nervous System Disease, 2023 Background Changes in brain connectivity occur in patients with multiple sclerosis (MS), even in patients under disease-modifying therapies. Using magnetic resonance imaging (MRI) to asses patients treated with disease-modifying therapies, such as ...
Diogo G. Corrêa +6 more
doaj +1 more source
Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers
Arquivos de Neuro-Psiquiatria, 2015 Objective Analyze the demographics, clinical characteristics, efficacy and safety of natalizumab treatment in Brazilian patients with multiple sclerosis (MS) followed up for at least 12 months, in two tertiary MS care centers in São Paulo.Method We ...
Enedina Maria Lobato de Oliveira +5 more
doaj +1 more source
Therapeutic Advances in Neurological Disorders, 2022 Background: For treatment of relapsing-remitting multiple sclerosis (RRMS), a broad range of disease-modifying therapies (DMT) is available. However, few comparative effectiveness studies between different drugs have been performed.
Katrin Pape +7 more
doaj +1 more source